Jeantet advises Sartorius Stedim Biotech on the acquisition of Novasep’s chromatography process equipment division

 

Paris, 6 January 2021 – Sartorius Stedim Biotech, a leading international partner of the biopharmaceutical industry, today announced it has entered into an agreement to acquire the chromatography process equipment division of Novasep. The parties agreed not to disclose the purchase price until the necessary regulatory approvals have been obtained.

Novasep’s division expects to generate sales revenue of approximately 37 million euros in 2020 at double-digit profit margins and employs approximately 100 people, the majority of whom work at its Pompey site in northern France and some in the USA, China and India. The proposed transaction is subject to antitrust approvals and the information and consultation of Novasep’s works council and is expected to close during the first half of 2021.

Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry. As a total solutions provider, the company helps its customers to manufacture biotech medications safely, rapidly and economically. Headquartered in Aubagne, France, Sartorius Stedim Biotech is quoted on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and an international network of sales companies, Sartorius Stedim Biotech has a global reach. The Group has been annually growing by double digits on average and has been regularly expanding its portfolio by acquisitions of complementary technologies. In 2019, the company employed approx. 6,200 people, and earned sales revenue of 1,440.6 million euros.

Novasep is a global provider of cost-effective and sustainable manufacturing solutions for life sciences molecules and fine chemicals. Novasep’s unique offering includes process development services, purification equipment and turnkey processes, contract manufacturing services and complex active molecules to serve pharmaceutical, biopharmaceutical, fine chemical, food and functional ingredients, as well as fermentation and chemical commodities industries.

Sartorius Stedim Biotech was advised by Jeantet with a team lead by Karl Hepp de Sevelinges (partner, Corporate/M&A), including Michael Samol (counsel, Corporate/M&A), Robert d’Orglandes (associate, Corporate/M&A), Laetitia Ternisien (counsel, Employment) and Gabriel di Chiara (counsel, Tax).

The firm Milbank LLP has worked closely with Jeantet, notably with Michael Bernhardt (partner, Corporate/M&A) and Alexander Rinne (partner, Antitrust), as well as the firm GvW Graf von Westphalen for Chinese law aspects.

Novasep was advised by White & Case LLP with a team lead by François Leloup (partner, Corporate/M&A), including Delphin Boucher (counsel, Corporate/M&A), Alexandre Jaurett (partner, Employment) and Orion Berg (counsel, Regulatory). Teams in the New-York and Washington offices have been involved on US law aspects and a team in the Shanghai office has been involved on Chinese law aspects.

Our last press releases

Jeantet advises LIDL on the acquisition of 19 supermarkets under the AUCHAN brand

Paris, July 25, 2025 – Jeantet advised the retail chain Lidl on the planned acquisition of 19 supermarkets currently operated under the Auchan banner. Auchan’s employee representative bodies are currently being consulted regarding the contemplated transaction. The completion of the deal remains subject to the fulfilment of several conditions, including clearance from the French Competition […]

Paris | CORPORATE – M&A – PRIVATE EQUITY

+

Jeantet advises a consortium of banks on the financing of the acquisition and refurbishment of hotel Paris-Charles de Gaulle by LUITEN VAN DER VALK GROUP

Paris, July 23, 2025 – Jeantet has advised ING BANK N.V., COÖPERATIEVE RABOBANK U.A. and ABN AMRO BANK N.V., in connection with a structured secured financing to LUITEN VAN DER VALK hotel and leisure group for the acquisition of the SHIR, a company owning the Atrium Hotel & Conference Centre Paris – Charles de Gaulle, […]

Paris | BANK-FINANCE-REGULATORY

+

Jeantet advises DREAMPATH DIAGNOSTICS on the acquisition of a stake by SUMMIT PARTNERS

Paris, July 16, 2025 – Jeantet advised Dreampath Diagnostics, a group specializing in automation and traceability of anatomical pathology samples, on Summit Partners’ acquisition of a minority stake. The transaction aims to accelerate Dreampath Diagnostics’ international growth and strengthen its offering of solutions for digitizing laboratory processes. Founded in 2012, the Dreampath Diagnostics group offers […]

Paris

+

Jeantet advises COGELEC and the shareholders of COGELEC DEVELOPPEMENT, majority shareholder of COGELEC, in the context of the proposed acquisition of COGELEC DEVELOPPEMENT by LEGRAND, prior to the filing of a simplified tender offer on COGELEC shares

Paris, July 11, 2025 – Jeantet advises Cogelec (a company listed on the Euronext Growth Paris market), French specialist of the housing access control, as well as the shareholders of Cogelec Développement, indirect majority shareholder of Cogelec, in the context of the contemplated acquisition of the Cogelec Développement shares by Legrand (a company listed on […]

Paris | CAPITAL MARKETS AND STOCK EXCHANGE LAW

+

Jeantet advises Oxylabs in connection with its acquisition of Scrapingbee

Paris, July 4, 2025 – Jeantet advised Oxylabs, one of the market-leading companies in web scraping solutions, in connection with its acquisition of ScrapingBee, a French fast-growing web scraping company known for its developer-friendly solutions. Through this strategic acquisition, Oxylabs significantly expands the Oxylabs group’s ecosystem as well as its target clientele, now addressing direct […]

Paris | CORPORATE – M&A – PRIVATE EQUITY

+

Jeantet advises AEQUITA on the acquisition of european olefins et polyolefins assets from chemicals group LYONDELLBASELL

Paris, June 27, 2025 – Jeantet acted as French legal counsel to AEQUITA SE & Co. KGaA, a global industrial group headquartered in Munich, in connection with the signing of an agreement and entry into exclusive negotiations to acquire four European olefins and polyolefins assets from chemicals group LyondellBasell. The transaction covers plants located in […]

Paris | CORPORATE – M&A – PRIVATE EQUITY

+

Jeantet assists Melvan in its €25 million fundraising to accelerate its development in France

Paris, June 26, 2025 – Jeantet assisted Melvan, a multi-technology renewable energy producer and developer, in opening its capital to a consortium of investors composed of Bpifrance, through its France Investissement Énergie Environnement 2 fund, IDIA Capital Investissement, through its Crédit Agricole Energie & Economie Bas Carbone I fund, and a pool of investors from […]

Paris | CORPORATE – M&A – PRIVATE EQUITY | PUBLIC LAW – PUBLIC CONTRACTS | ENERGY AND NATURAL RESOURCES LAW | BANKING AND FINANCE LAW | EMPLOYMENT

+

Ginestié and Jeantet form a strategic partnership

Paris, June 20, 2025 – Jeantet and Ginestié Paley-Vincent announce the entry into a strategic partnership, effective October 1, 2025. This alliance is based on a common vision of the legal profession, its evolution, and its requirements. This partnership represents a significant milestone in the development of Ginestié Paley-Vincent, which has decided to join forces […]

Paris

+

JEANTET ASSISTS SIRIUS SPACE SERVICES IN ITS ACQUISITION OF S.E.R.M FROM THE FIVES GROUP

Paris, June 19, 2025 – Jeantet advises Sirius Space Services, a player in the space sector, on the acquisition of S.E.R.M (Société d’Études et de Réalisations Mécaniques), a historic precision machining site, accompanied by a strategic partnership with the Fives group and its subsidiary AddUp, a specialist in metal additive manufacturing. With this strategic acquisition, […]

Paris | CORPORATE – M&A – PRIVATE EQUITY

+

JEANTET ADVISES CENTREON IN CONNECTION WITH ITS ACQUISITION OF QUANTA IO

Paris, June 13, 2025 – Jeantet is advising Centreon, a trusted partner in digital performance monitoring, in connection with its acquisition of Quanta.io, a French software company renowned for its expertise in Web Performance and Green IT. Through this strategic acquisition, Centreon becomes the only private and independent vendor to offer an end-to-end observability platform […]

Paris | CORPORATE – M&A – PRIVATE EQUITY

+

Jeantet advises CUREETY in connection with its acquisition of CONTINUUM PLUS SANTÉ

Paris, June 6, 2025 – Jeantet is advising Cureety in connection with its acquisition of the company Continuum Plus Santé, both specializing on remote monitoring for cancer patients.  Through this acquisition, Cureety consolidates its leadership position in remote monitoring in oncology, particularly through better management of the “Hospital-City-Home” care pathway by enabling the involvement of […]

Paris | CORPORATE – M&A – PRIVATE EQUITY

+